Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
AssigneeMayo Foundation for Medical Education and Research
InventorsGerald F. Swiss, Jesse Crowne, Svetomir N. Markovic, Wendy K. Nevala
Life of this patent
Estimating the term…
Abstract
Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).
Claims24
A method for treating a breast cancer cell characterized as having a triple negative phenotype, comprising administering to the breast cancer cell a composition comprising a therapeutic amount of nanoparticle complexes, the complexes comprising:
- a) albumin;
- b) an effective amount of a binding agent having an antigen-binding portion that binds to a target antigen expressed by said cancer cells so as to provide directional guidance of the nanoparticle complexes to said cells;
- and c) an effective amount of paclitaxel.
A method for treating a patient afflicted with breast cancer characterized as having a triple negative phenotype and further characterized as expressing an antigen, said method comprises administering to the patient a therapeutic amount of nanoparticle complexes, said nanoparticle complexes comprising:
- a) albumin;
- b) an effective amount of a binding agent having an antigen-binding portion that binds to the antigen so as to provide directional guidance of the nanoparticle complexes to said cancer;
- and c) an effective amount of paclitaxel.
A method for treating a patient afflicted with breast cancer characterized as having a triple negative phenotype and further characterized as expressing VEGF, said method comprises treating said patient with a composition comprising a therapeutic amount of nanoparticle complexes, said nanoparticle complexes comprising:
- a) human serum albumin;
- b) an effective amount of bevacizumab or a biosimilar version thereof so as to provide directional guidance of the nanoparticle complexes to said cells;
- and c) effective amount of paclitaxel.
Dependencies are inferred from the claim text.